Advanced Enzyme Technologies Ltd.

₹305.2

2.2 (0.7%)

ADVENZYMES Share Price

Pharmaceuticals & Biotechnology

As on August 19, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryBiotechnology

Market Cap₹ 3,428 Cr

P/E Ratio20.25

Dividend Yield0.88 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	303.79	Bullish
10-DMA	306.76	Bearish
20-DMA	311.9	Bearish
50-DMA	328.68	Bearish
100-DMA	332.17	Bearish
200-DMA	316.2	Bearish

Historical Performance

1 Year

-3.6%

3 Years

-7.3%

5 Years

-19.2%

10 Years

9.7%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Net Sales	7,458	6,369	6,239	5,406	5,294
Total Expenditure	5,165	4,414	4,185	3,831	3,268
Other Income	357	330	370	255	64
Operating Profit	2,650	2,286	2,423	1,830	2,090
Interest	37	46	41	35	30
Depreciation	401	366	352	350	350
Profit Before Tax	2,325	1,874	1,878	1,404	1,711
Consolidated Net Profit	1,687	1,311	1,333	1,056	1,196
Adjusted EPS	15	12	12	9	11

Compounded Sales Growth

10 Years:20.5

5 Years:8.2

3 Years:6.6

TTM:3.2

Compounded Profit Growth

10 Years:17.3

5 Years:2.9

3 Years:9.8

TTM:5.2

Stock Price CAGR

10 Years:0.9

5 Years:-4

3 Years:-2.5

TTM:-1.7

Return on Equity

10 Years:8.2

5 Years:10.7

3 Years:11.9

last year:15.1

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Share Capital	224	224	224	224	224
Total Reserves	16,004	13,935	12,987	12,127	10,656
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	440	462	437	488	594
Other Current Liabilities	482	402	442	432	366
Short Term Borrowings	112	111	176	50	19
Total Liabilities	18,339	16,112	15,212	14,105	12,602
Capital Work in Progress	512	217	307	156	96
Long Term Loans & Advances	405	238	190	163	175
Currents Investments	5,838	4,803	4,028	3,596	1,019
Short Term Loans and Advances	129	107	241	87	120
Total Current Assets	10,436	8,799	8,097	7,221	6,044
Total Assets	18,339	16,112	15,212	14,105	12,602
Adjusted Book Value	145	127	118	110	97

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a moderate PE of 20.25, suggesting fair valuation relative to earnings.
Over the last three years, the stock delivered a weak 3-year price CAGR of -2.5%, indicating poor shareholder returns.
The stock carries a beta of 1.0, indicating volatility broadly in line with the market.
In the last financial year, the company reported an EBITDA of ₹2650 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹7458 million, suggesting a mid-sized operation.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 982614.3

No. of Shares: 3220 (Approx)

Performance:-1.7%

-17385.7

NIFTY Performance: -3.9%

1 day Top Gainers